(18)F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib

SIMPLE SUMMARY: In patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC), therapeutic options are limited. In the “Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT)”, Lenvatinib significantly prolonged the progression-free survival, resulting...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmaddy, Freba, Burgard, Caroline, Beyer, Leonie, Koehler, Viktoria Florentine, Bartenstein, Peter, Fabritius, Matthias P., Geyer, Thomas, Wenter, Vera, Ilhan, Harun, Spitzweg, Christine, Todica, Andrei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830971/
https://www.ncbi.nlm.nih.gov/pubmed/33467085
http://dx.doi.org/10.3390/cancers13020317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830971/
https://www.ncbi.nlm.nih.gov/pubmed/33467085
http://dx.doi.org/10.3390/cancers13020317

Ejemplares similares